About the Company
NEMUS Bioscience Inc. is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids. These molecules display pleiotropic activity by virtue of selectively binding to two types of cannabinoid receptors (CB1 and CB2 receptors) located throughout multiple organ systems in the body. NEMUS Bioscience Inc. is developing novel and proprietary classes of product candidates that are designed to improve therapeutic options through enhanced chemical engineering that allow drug candidates to have more predictable bioavailability and pharmacokinetics leading to optimized efficacy and safety.
NEMUS Bioscience Inc., a Nevada corporation is listed on the OTC Bulletin Board and trading under the symbol NMUS.
Nemus Bioscience Files Arbitration Petition Against Schneider Finance, LLC and SB Securities, Ltd. for Failure to Close $20 Million Financing and Failure to Honor Guarantee
COSTA MESA, CA–(Marketwired – Nov 9, 2017) – NEMUS Bioscience, Inc. ( OTCQB : NMUS ) (the “Company”) today announced that it has submitted a demand commencing arbitration against Schneider Finance, LLC and SB Securities, Ltd., both affiliates of Schneider Brothers Ltd., as well as...
NEMUS Bioscience Announces Presentation of CBD-analogue Therapeutic Data Related to Neuropathic Pain (NB2111) and Ocular Diseases (NB2222) at Upcoming Scientific Meetings
COSTA MESA, CA–(Marketwired – Nov 6, 2017) – NEMUS Bioscience, Inc. ( OTCQB :NMUS ) announced that data obtained from the company’s research and development partner, the University of Mississippi (UM), will be presented at upcoming scientific meetings in November. Research under the direction...
COSTA MESA, CA–(Marketwired – Jul 11, 2017) – NEMUS Bioscience, Inc. ( OTCQB : NMUS ) (the “Company”) today announced an update to its news release dated May 4, 2017 with respect to the signing of a private placement...
Nemus Bioscience Announces NB1111 Data Presentation at the 27th Annual Symposium of the International Cannabinoid Research Society (ICRS)
COSTA MESA, CA–(Marketwired – Jun 22, 2017) – NEMUS Bioscience, Inc. ( OTCQB : NMUS ) announced that tetrahydrocannabinol (THC) derived from NB1111, the proprietary Nemus prodrug of THC, achieved significant tissue concentrations in multiple compartments of the eye...